| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IGLL5 |
| Uniprot No | B9A064 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 36-214aa |
| 氨基酸序列 | HGLLRPMVAPQSGDPDPGASVGSSRSSLRSLWGRLLLQPSPQRADPRCWPRGFWSEPQSLCYVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS |
| 预测分子量 | 26.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IGLL5重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**: "IGLL5 is required for B cell development via regulation of recombination-activating genes"
**作者**: Smith A, et al.
**摘要**: 研究揭示了IGLL5在B细胞发育中的关键作用，发现其通过调控重组激活基因(RAG)的表达促进免疫球蛋白基因重排。重组蛋白实验表明，IGLL5缺失导致前B细胞中V(D)J重组异常，影响抗体多样性生成。
2. **文献名称**: "Structural and functional characterization of recombinant IGLL5 in early lymphoid development"
**作者**: Chen L, et al.
**摘要**: 通过表达和纯化人源IGLL5重组蛋白，解析其晶体结构，发现其与λ5蛋白形成复合物，协同调控前B细胞受体(pre-BCR)信号通路。功能实验证实IGLL5重组蛋白对B细胞成熟至关重要。
3. **文献名称**: "IGLL5 dysregulation in B-cell malignancies: Implications for recombinant protein-based therapeutics"
**作者**: Kim H, et al.
**摘要**: 分析IGLL5在B细胞肿瘤中的异常表达，发现其重组蛋白可通过恢复pre-BCR信号抑制恶性细胞增殖。体外实验显示，重组IGLL5联合化疗药物可增强肿瘤细胞凋亡，提示其潜在治疗价值。
---
注：以上文献信息为模拟示例，实际文献需通过学术数据库(如PubMed、Web of Science)检索确认。
**Background of IGLL5 Recombinant Protein**
IGLL5 (Immunoglobulin Lambda Like Polypeptide 5), also known as λ5. is a critical component of the pre-B cell receptor (pre-BCR) complex, which plays an essential role in early B cell development. It belongs to the immunoglobulin superfamily and is encoded by the *IGLL5* gene located on chromosome 22 in humans. Structurally, IGLL5 contains a conserved immunoglobulin-like domain that facilitates interactions with other pre-BCR components, such as VpreB and the immunoglobulin heavy chain (IgH), forming a surrogate light chain. This complex is vital for mediating checkpoint signaling during the pro-B to pre-B cell transition, ensuring proper immunoglobulin heavy chain rearrangement and clonal selection.
Dysregulation of IGLL5 has been linked to immune disorders and malignancies. For example, mutations or deletions in *IGLL5* can impair B cell maturation, leading to immunodeficiencies. Conversely, aberrant expression is observed in certain B cell leukemias, highlighting its dual role in health and disease. Recombinant IGLL5 protein, produced via expression systems like *E. coli* or mammalian cells, retains the functional domains necessary for structural and biochemical studies. Researchers utilize it to investigate pre-BCR signaling mechanisms, model B cell development defects, or screen therapeutic agents targeting B cell malignancies.
The production of recombinant IGLL5 often involves affinity tags (e.g., His-tag) for purification, enabling high-purity yields for *in vitro* assays, antibody generation, or structural analyses (e.g., X-ray crystallography). Its applications extend to understanding immune tolerance, autoimmune diseases, and improving engineered B cell therapies. As a tool, IGLL5 recombinant protein bridges basic immunology research with translational efforts in diagnostics and targeted treatments.
×
